Therapeutic drug monitoring (TDM) of antiretroviral drugs was performed in a prospective study before and at day 28 after start of treatment with 4 mg of rosiglitazone for combined lipodystrophy syndrome. Drug levels were measured in the morning fasting, and 0.5, 1, 2, 4, 6 and 8 h after standardized drug intake. Mean Cmax of nevirapine (n=4) was reduced significantly [-0.44; 95% CI -0.86 to -0.01]. Furthermore, there was a consistent trend to a reduction in the geometric mean ratio (GMR) of Cmax (5%), Cmin (11%) and AUC (4%). Routine TDM is recommended for patients treated with rosiglitazone and nevirapine. Further studies on the interaction of rosiglitazone with ARV drugs are necessary.
Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients. Oette M, Kurowski M, Feldt T, et al. J Antimicrob Chemother, 2005, 56(2):416-419.